KBI establishes Parkinson Disease (PD) Models through:

1. Systemic MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Administration  
·  Intramuscular administration of MPTP                       
·  Intravenous administration of MPTP
·  Systemic bilateral symptom model

2. Local CNS MPTP Administration
·  Stereotaxic intra-nigral injection
·  Specific delivery of MPTP to the substantia nigra (SN), unilateral or bilateral
·  Eliminate systemic non-PD toxicity
·  Targeted unilateral or bilateral symptom model

PD Model evaluation:
1.  Behavioral analysis: (Kurlan’s scale)
2.  Imaging analysis:
    MRI (Structural change)
    SPECT (Functional change)
3.  Biochemical analysis: dopamine & metabolites
4.  L-DOPA treatment: positive drug to relieve the PD symptoms
5.  Pathological analysis: Immunohistochemistry (Tyrosine Hydroxylase neuron staining)